Cannabis Law and Access in Singapore

Zero tolerance, genuinely

Fifteen grams. That's the threshold above which Singaporean law presumes you intend to traffic cannabis , and trafficking carries a mandatory death penalty under the Misuse of Drugs Act (Cap 185). I've spent years reading scheduling instruments and access legislation across a range of jurisdictions, and few frameworks communicate their intent as bluntly as Singapore's. There is no ambiguity built into the system. That's a deliberate policy choice, and it shapes everything downstream.

This article is a factual account of Singapore's legal framework for cannabis. It is not Australian law, and nothing here should be read as legal advice for any jurisdiction. Australian readers should note that even where cannabis is legally accessible in Australia under the TGA's frameworks, those protections stop entirely at the border.

How Singapore classifies cannabis

Under the Misuse of Drugs Act, cannabis , including the plant, resin, and any preparation containing tetrahydrocannabinol (THC) , is listed as a Class A controlled drug. Class A is the most serious category. There is no state-level variation, no medicinal carve-out for personal possession, and no decriminalisation framework at any level of enforcement. The law applies uniformly across the city-state.

Cannabidiol (CBD) is not treated differently from THC under Singaporean law. This is a point that catches people out. In Australia, a low-dose CBD product sits under Schedule 4 as a prescription-only medicine and, in certain formulations, has been accessible over the counter since 2021. That distinction simply does not exist in Singapore. Any CBD product derived from cannabis is captured under the same prohibition as any other cannabis derivative.

Hemp-derived products, CBD oils, cannabis-infused foods; all prohibited. If it comes from the cannabis plant and contains any scheduled cannabinoid, it is illegal to possess, import, sell, or consume on Singaporean soil.

Penalties: the actual numbers

The penalty scale under the Misuse of Drugs Act is worth setting out clearly, because it escalates sharply with quantity.

For possession or consumption, a first offence can result in up to 10 years imprisonment, a fine of up to S$20,000, or both. These are not theoretical maximums that courts rarely impose. Singapore's courts apply the legislation consistently.

Trafficking thresholds are defined by weight:

• More than 15 grams of cannabis: presumed to be for trafficking
• 330 grams or more: mandatory minimum 20 years imprisonment, 15 strokes of the cane
• 500 grams or more: death penalty (mandatory, with a limited discretionary exception introduced in 2012 for couriers who cooperate with authorities and are certified as not playing a substantive role)

These numbers apply to cannabis mixture. For cannabis resin (hashish), the thresholds are lower: the death penalty threshold sits at 200 grams. For pure THC in extracted or concentrated form, the thresholds are lower again.

The 2012 amendment, the Misuse of Drugs (Amendment) Act, introduced limited judicial discretion for the death penalty in narrow circumstances. It didn't soften the framework in any meaningful way for possession or low-level trafficking.

The consumption offence: it travels with you

One aspect of Singaporean law that surprises Australian readers is the extraterritorial consumption provision. Under section 8(b) read together with section 31 of the Misuse of Drugs Act, a Singaporean citizen or permanent resident can be charged in Singapore for consuming cannabis abroad, if a urine or hair sample taken after their return tests positive.

This doesn't apply to Australian citizens. But it illustrates the philosophical approach underpinning the whole framework: Singapore treats cannabis use as a public health and social order issue that the state has a legitimate interest in pursuing wherever it occurs.

For Australian travellers, the practical implication is simpler: any cannabis use in the period before travel could result in a positive test at Singapore's border if authorities request one, and possession of any amount; including residue in a container, constitutes an offence.

Is there any legal medical access?

Sort of, but the pathway is extremely narrow and almost entirely inaccessible in practice. Singapore's Health Sciences Authority (HSA) operates under a framework that allows for the importation of certain controlled substances for genuine medical purposes, subject to HSA approval. In principle, a patient with a documented clinical need could apply to import a cannabis-derived medicine.

In practice, the approved products are vanishingly few. The HSA approved nabiximols (a cannabis-derived oromucosal spray) in 2022, making Singapore technically one of the first Southeast Asian jurisdictions to allow any cannabis medicine. But this is a highly restricted, specialist-only pathway. There is no equivalent to Australia's Special Access Scheme or Authorised Prescriber programme, no community pharmacy dispensing, and certainly no recreational or patient self-referral access.

For context: in Australia, medicinal cannabis products must be listed on or approved via the ARTG, and prescribing occurs under Schedule 8 (Controlled Drug) or Schedule 4 (Prescription Only) frameworks depending on the product. Even that system, for all its bureaucratic weight, is far more accessible than what exists in Singapore.

Honestly, "medical access" in Singapore is, at this point, more of a regulatory footnote than a functional pathway for most patients.

Regional context and recent debates

Singapore sits in a region with broadly similar laws. Thailand made headlines with its partial decriminalisation in 2022 before the government began walking that back in 2023 and 2024 under new political leadership. Malaysia and Indonesia retain severe penalties comparable to Singapore's. The Philippines enforces mandatory rehabilitation for drug users alongside criminal penalties.

There has been some public debate within Singapore about whether the framework needs to modernise; particularly among younger Singaporeans who follow developments in Canada, the United States, and Germany. The government's position, stated clearly and repeatedly by senior ministers including in parliamentary sessions, is that the current framework will be maintained. The Central Narcotics Bureau (CNB) frames the policy as a public health success story, pointing to comparatively low rates of drug use in population surveys.

Whether strict enforcement or social and cultural factors drive those numbers is a genuinely contested empirical question. I'd argue the causal attribution is harder to establish than the CNB's framing suggests, but that debate is well outside the scope of a regulatory description.

What is clear is that there is no legislative reform on the horizon. Singapore has not signalled any intention to follow Thailand, Germany, or any other jurisdiction toward even partial decriminalisation.

What Australian travellers actually need to know

I had this conversation with a colleague at a symposium near the National Convention Centre in Canberra last year, she was travelling through Changi Airport and wondered whether carrying a TGA-approved medicinal cannabis product for personal use was permissible with the right documentation. The short answer is no. The longer answer is also no.

Singapore does not recognise foreign prescriptions as authorising possession of a controlled substance. A valid Australian prescription for a Schedule 8 medicinal cannabis product provides no legal protection in Singapore. Import without prior HSA approval is an offence regardless of the traveller's home country legal status.

If you are an Australian patient with a current medicinal cannabis prescription and you are transiting through or travelling to Singapore, you need to either leave your medication at home or obtain prior HSA approval, a process that requires substantial lead time, specialist involvement, and is not guaranteed. The Australian Government's Smartraveller advisory for Singapore references this explicitly.

This matters for understanding why jurisdiction-specific knowledge is not optional. The endocannabinoid system is the same in every human body regardless of passport, but the legal frameworks governing access to cannabinoids are wildly different depending on where you stand. A compound like CBD occupies a completely different regulatory position in Australia, Singapore, Germany, and the United States; sometimes even within a single country across different states.

Knowing your home country's rules is a start. Assuming they travel with you is where people get into serious difficulty.

Sources

• Misuse of Drugs Act (Cap 185), Singapore Statutes Online, Attorney-General's Chambers
• Controlled Drugs, Health Sciences Authority Singapore
• Singapore Travel Advisory; Smartraveller, Australian Government
• Cannabis Drug Information, Central Narcotics Bureau Singapore

, Marcus Hale, Regulatory researcher, TGA & access law